Clinical advances in targeting epigenetics for cancer therapy
| Autor: | Shengrui Feng, Daniel D. De Carvalho |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Transcription Genetic Antineoplastic Agents Disease Bioinformatics Biochemistry Epigenesis Genetic Histones 03 medical and health sciences 0302 clinical medicine Neoplasms Humans Medicine Molecular Targeted Therapy Epigenetics Molecular Biology Regulation of gene expression business.industry Cancer Drugs Investigational Cell Biology DNA Methylation medicine.disease Combined Modality Therapy Chromatin Neoplasm Proteins 3. Good health Clinical trial Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Cancer cell DNA methylation Immunotherapy business Epigenetic therapy |
| Zdroj: | The FEBS Journal. 289:1214-1239 |
| ISSN: | 1742-4658 1742-464X |
| Popis: | The appropriate coordination between epigenetic regulators is essential for spatial and temporal regulation of gene expression and maintenance of cell identity. Cancer is a disease driven by both genetic and epigenetic alterations. The widespread dysregulation and reversible nature of epigenetic alterations confer cancer cells with vulnerabilities for therapeutic interventions. Over the past decades, remarkable progress has been made in developing drugs that target epigenetic regulators, with many drugs under evaluation in clinical trials. Here, we summarize the epigenetic drugs currently in clinical investigations and highlight the potentials and challenges in their implication to treat cancer. We also discuss the preclinical and clinical results of combination therapies with epigenetic drugs and other therapies such as targeted and immune-based therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text